Paysign and ImmunoTek Collaborate in Support of COVID-19 Convalescent Plasma Collection
December 10 2020 - 8:00AM
Business Wire
Partnership Focuses on Motivating Recovered
Plasma Donors for Development of New Therapeutic
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card
programs, digital banking services, and payment processing, along
with ImmunoTek Bio Centers LLC, a growing biotech company focused
on source plasma collection, today announced their successful
efforts to integrate COVID-19 convalescent plasma collection with a
prepaid card program for donor compensation.
ImmunoTek has established source plasma collection from
recovered COVID-19 patients on site at Mount Sinai. Once collected,
the plasma will be used to develop and manufacture COVID-19
hyperimmune globulin for evaluation in clinical trials. The trial
aims to receive potential emergency use authorization or broader
FDA approval for the patient therapy.
Paysign, a longtime ImmunoTek partner, has built and refined a
prepaid debit card program for the plasma collection industry that
addresses their unique set of needs, while motivating and rewarding
source plasma donors to increase both the frequency of donations
and retention of repeat donors. Paysign’s integrated solution
enhances the donor experience with a customized prepaid card
program designed to also streamline the payments process for
ImmunoTek and their clinical trial partners.
“Being a partner to the plasma collection industry since 2011
has uniquely positioned us to provide the precise set of services
and technologies that are aiding companies in their critical work
of source plasma collection,” said Mark Newcomer, president and CEO
of Paysign. “We are honored to work hand-in-hand with ImmunoTek in
establishing this solution for donors, including at the Mount Sinai
Health System where ImmunoTek currently is making significant
efforts in supporting collection of convalescent plasma for
COVID-19 hyperimmune globulin clinical trials.”
“During the development of this extremely important and
time-sensitive therapy, we are thankful for the support of our
longtime payments partner, Paysign,” said Jerome Parnell III, CEO
and president, ImmunoTek Bio Centers. “We knew their
tried-and-tested donor compensation program would help us
facilitate the collection process for vital plasma needed for the
COVID-19 hyperimmune globulin clinical trials.”
For more information about Paysign’s suite of solutions, please
visit paysign.com/solutions. For more information about ImmunoTek
Bio Centers or to find a donation center, please visit
immunotek.com.
About Paysign
Paysign, Inc. is a leading provider of prepaid card programs and
integrated payment processing services designed for businesses,
consumers, and government institutions. Incorporated in 2001 and
headquartered in southern Nevada, the company creates customized,
innovative payment solutions for clients across all industries,
including pharmaceutical, healthcare, hospitality, and retail.
Built on the foundation of a reliable payments platform, Paysign’s
end-to-end technologies securely enable digital payout solutions
and facilitate the distribution of funds for donor compensation,
copay assistance, customer incentives, employee rewards, travel
expenses, per diem, as well as reimbursements and rebates.
Paysign’s solutions lower administrative costs, streamline
operations, increase revenues, accelerate product adoption, and
improve customer, employee, and channel partner loyalty. To learn
more, visit paysign.com.
About ImmunoTek Bio Centers LLC
ImmunoTek Bio Centers is an emerging bio-tech company committed
to the safe collection and procurement of human blood plasma from
the public. The management team has extensive experience in the
blood, plasma, and biopharma industries. Through contracts and
strategic agreements with pharmaceutical companies, IMMUNOTEK is
fully capable of constructing, opening, FDA/EU licensing, and
managing multiple plasma collection sites and plasma supply
contracts in order to meet on going demand in the plasma proteins
therapeutics market. Growth of current therapeutic drugs and
vaccines as well as additional new therapeutic indications expected
to put considerable strain on global blood plasma supply. IMMUNOTEK
currently owns and operates plasma collection centers in the USA
and has over 40 collection centers in development through 2020. For
more information, please visit www.immunotek.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201210005203/en/
Paysign Media Relations Alicia Ches Director, Marketing
702.749.7257 pr@paysign.com
Paysign Investor Relations Jim McCroy EVP, Strategic Development
702.749.7269 ir@paysign.com
ImmunoTek Bio Centers Pam Farris Executive Administrative
Assistant 337.500.1294 pfarris@immunotek.com
Paysign (NASDAQ:PAYS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paysign (NASDAQ:PAYS)
Historical Stock Chart
From Sep 2023 to Sep 2024